Improving access to second-line antiretrovirals.
The Lancet
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D004345:Drug Industry / Q000191:economics*; D014943:Global Health; D017320:HIV Protease Inhibitors / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000191:economics* / Q000627:therapeutic use; D019438:Ritonavir / Q000191:economics* / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir